KCNC 60 Minutes September 26, 2016
For adults with advanced nonsmall cell lung cancer previously treated with platinumbased chemotherapy, including those with an abnormal alk or e. G. F. R. Gene whove tried an fdaapproved targeted therapy, nivolumab. Opdivo demonstrated longer life and is the most prescribed immunotherapy for these patients. Opdivo significantly increased the chance of living longer versus chemotherapy. No biomarker testing is required with opdivo, though physicians may choose to do so. Opdivo works with your immune system. Opdivo can cause your immune system to attack normal organs and tissues in your body and...